BigHat Bio
John Corbin is an accomplished biochemist with extensive experience in the biotechnology industry. Currently serving as the Chief Development Officer at BigHat Biosciences since May 2023, John previously held significant roles at Tizona Therapeutics, Inc. as Chief Technology Officer and SVP from November 2016 to June 2023, where responsibilities included overseeing CMC, Protein Sciences, and Antibody Discovery. At Gilead Sciences from August 2013 to November 2016, John was the Vice President of Antibody Development and a Senior Research Scientist, leading initiatives in therapeutic antibody engineering. John's earlier experience includes being an Associate Director at XOMA, where successful preclinical projects were developed, and a Postdoctoral Researcher at the University of Colorado, focusing on human protein signaling domains. John earned a Ph.D. in Biochemistry, Biophysics, and Signaling Biology from the University of California, Santa Cruz.
This person is not in any teams
BigHat Bio
1 followers
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.